JP7618599B2 - 前立腺特異的膜抗原を標的とする放射性標識化合物 - Google Patents

前立腺特異的膜抗原を標的とする放射性標識化合物 Download PDF

Info

Publication number
JP7618599B2
JP7618599B2 JP2021576163A JP2021576163A JP7618599B2 JP 7618599 B2 JP7618599 B2 JP 7618599B2 JP 2021576163 A JP2021576163 A JP 2021576163A JP 2021576163 A JP2021576163 A JP 2021576163A JP 7618599 B2 JP7618599 B2 JP 7618599B2
Authority
JP
Japan
Prior art keywords
aromatic
group
xaa
groups
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021576163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537773A5 (enExample
JP2022537773A (ja
Inventor
リン，クオ－シュヤン
ベナール，フランソワ
クオ，ショウ－ティン
ジャン，ジョンシン
ペラン，ダヴィド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provincial Health Services Authority
Original Assignee
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provincial Health Services Authority filed Critical Provincial Health Services Authority
Publication of JP2022537773A publication Critical patent/JP2022537773A/ja
Publication of JP2022537773A5 publication Critical patent/JP2022537773A5/ja
Priority to JP2025002658A priority Critical patent/JP2025069156A/ja
Application granted granted Critical
Publication of JP7618599B2 publication Critical patent/JP7618599B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021576163A 2019-06-21 2020-06-19 前立腺特異的膜抗原を標的とする放射性標識化合物 Active JP7618599B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025002658A JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962865088P 2019-06-21 2019-06-21
US62/865,088 2019-06-21
US202063006643P 2020-04-07 2020-04-07
US63/006,643 2020-04-07
PCT/CA2020/050864 WO2020252598A1 (en) 2019-06-21 2020-06-19 Radiolabeled compounds targeting the prostate-specific membrane antigen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025002658A Division JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Publications (3)

Publication Number Publication Date
JP2022537773A JP2022537773A (ja) 2022-08-29
JP2022537773A5 JP2022537773A5 (enExample) 2023-06-26
JP7618599B2 true JP7618599B2 (ja) 2025-01-21

Family

ID=74036930

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576163A Active JP7618599B2 (ja) 2019-06-21 2020-06-19 前立腺特異的膜抗原を標的とする放射性標識化合物
JP2025002658A Pending JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025002658A Pending JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Country Status (9)

Country Link
US (2) US11504441B2 (enExample)
EP (1) EP3986872A4 (enExample)
JP (2) JP7618599B2 (enExample)
KR (1) KR20220024595A (enExample)
CN (2) CN114401947B (enExample)
BR (1) BR112021025810A2 (enExample)
CA (1) CA3144094A1 (enExample)
IL (1) IL288960B1 (enExample)
WO (1) WO2020252598A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
IL301342A (en) 2020-10-21 2023-05-01 Provincial Health Services Authority Novel CXCR4-targeting compounds
EP4263509A4 (en) * 2020-12-16 2024-12-04 The University of British Columbia RADIOACTIVELY LABELLED COMPOUNDS FOR TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
KR20230155494A (ko) * 2021-02-26 2023-11-10 테릭스 파마슈티컬스 (이노베이션스) 피티와이 엘티디 글루타메이트-우레아-라이신 유래(gul 유래) 전립선-특이적 막 항원(psma) 표적화 접합체의 고체상 합성 및 치료 및/또는 진단제의 전구체로서 이들의 용도
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
JP2024544870A (ja) * 2021-11-10 2024-12-05 スージョウ・ルイヘ・メディシン・テクノロジー・カンパニー・リミテッド Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用
EP4486756A1 (en) * 2022-03-04 2025-01-08 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
WO2024016071A1 (en) * 2022-07-18 2024-01-25 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CN118344391A (zh) * 2023-01-13 2024-07-16 浙江普利药业有限公司 一种新的用于硼中子捕获疗法的含硼化合物
CN118496305A (zh) * 2023-02-16 2024-08-16 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
CN116730983B (zh) * 2023-08-10 2023-11-03 山东大学 一种靶向前列腺特异性抗原的化合物及其制备方法与应用
EP4590664A1 (en) 2023-09-12 2025-07-30 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
WO2025055942A1 (en) 2023-09-12 2025-03-20 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
CN117045828A (zh) * 2023-10-12 2023-11-14 北京先通国际医药科技股份有限公司 212Pb标记的放射性化合物在制备治疗前列腺癌药物中的用途
CN119101006B (zh) * 2024-09-05 2025-11-07 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性标记物及制法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075583A1 (en) 2017-10-22 2019-04-25 British Columbia Cancer Agency Branch NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US7563433B2 (en) 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
CA2555597C (en) 2004-02-13 2016-06-14 The University Of British Columbia Radiolabeled compounds and compositions, their precursors and methods for their production
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
CA2669127C (en) 2006-11-08 2016-09-13 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
CA2926573C (en) 2007-06-26 2018-08-28 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
CA2731645C (en) 2007-07-24 2017-05-23 The University Of British Columbia Substituted aryl-fluoroborates as imaging agents
AU2009276423B2 (en) 2008-08-01 2014-10-30 The Johns Hopkins University PSMA-binding agents and uses thereof
WO2012094334A1 (en) 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
KR20140010096A (ko) 2011-03-01 2014-01-23 지이 헬쓰케어 리미티드 Ｐｅｔ 트레이서로서 방사능표지된 옥트레오테이트 유사체
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
WO2013028791A1 (en) 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
AU2013344778C1 (en) 2012-11-15 2024-06-27 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
US20140147381A1 (en) 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
CA2903281C (en) 2013-03-08 2022-11-29 The University Of British Columbia Substituted organofluoroborates as imaging agents
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN105849568B (zh) 2013-11-14 2018-05-04 恩多塞特公司 用于正电子发射断层术的化合物
CA2972058C (en) 2014-01-03 2022-05-24 British Columbia Cancer Agency Branch Compositions and methods for imaging cancer
WO2015135082A1 (en) 2014-03-13 2015-09-17 British Columbia Cancer Agency Branch Bradykinin receptor b1 targeting probes
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
CN108699087B (zh) * 2016-01-10 2022-05-17 不列颠哥伦比亚癌症局分支机构 靶向前列腺特异性膜抗原的18/19f标记的化合物
US11147889B2 (en) 2016-11-23 2021-10-19 Cancer Targeted Technology Llc Albumin-binding PSMA inhibitors
CN106967152B (zh) 2017-03-28 2019-11-26 江苏省原子医学研究所 一种氟-18标记的化合物及其制备方法与应用
KR102843240B1 (ko) 2017-05-24 2025-08-05 이테엠 이소토페 테크놀로기에스 뮈니치 에스이 신규 psma-결합제 및 이의 용도
CN110914274B (zh) * 2017-06-06 2022-08-26 透明医药有限公司 放射性药物、放射成像剂及其用途
SMT202400439T1 (it) 2017-12-11 2024-11-15 Univ Muenchen Tech Ligandi di psma per la formazione di immagini e endoradioterapia
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
JP7500551B2 (ja) 2018-09-28 2024-06-17 ウニベルジテート ハイデルベルク 前立腺特異的膜抗原（ｐｓｍａ）の標識化阻害剤、画像化剤としてのそれらの使用、及びｐｓｍａ発現がんの処置のための医薬剤
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
KR20210110834A (ko) 2018-12-18 2021-09-09 프로빈셜 헬스 서비시즈 오쏘리티 이중 방식의 18f-표지된 테라노스틱 화합물 및 그 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075583A1 (en) 2017-10-22 2019-04-25 British Columbia Cancer Agency Branch NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kuo, H.-T. et al.，"A 177Lu-labeled albumin-binder-conjugated PSMA-617 derivative with greatly enhanced radiation dose delivered to LNCaP tumor xenografts"，Journal of Nuclear Medicine, [online]，2018年，Vol. 59, (supplement 1)，7，[令和6年8月2日検索], インターネット，<URL: https://jnm.snmjournals.org/content/59/supplement_1/7>

Also Published As

Publication number Publication date
IL288960B1 (en) 2026-03-01
US11504441B2 (en) 2022-11-22
JP2025069156A (ja) 2025-04-30
US20230114807A1 (en) 2023-04-13
WO2020252598A1 (en) 2020-12-24
CN119431260A (zh) 2025-02-14
IL288960A (en) 2022-02-01
CN114401947B (zh) 2024-11-29
US20210338851A1 (en) 2021-11-04
EP3986872A4 (en) 2024-02-21
AU2020296488A1 (en) 2022-01-20
JP2022537773A (ja) 2022-08-29
CA3144094A1 (en) 2020-12-24
KR20220024595A (ko) 2022-03-03
CN114401947A (zh) 2022-04-26
EP3986872A1 (en) 2022-04-27
BR112021025810A2 (pt) 2022-05-10

Similar Documents

Publication Publication Date Title
JP2025069156A (ja) 前立腺特異的膜抗原を標的とする放射性標識化合物
JP7659268B2 (ja) デュアルモード１８ｆ標識セラノスティック化合物及びその使用
AU2020257786B2 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
US20250186627A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
JP2025513489A (ja) Ｃｘｃｒ４標的化合物、およびその作製方法、およびその使用方法
US20240018110A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2024016071A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
US20250195702A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
AU2020296488B2 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
BR122025011654A2 (pt) Compostos radiomarcados de direcionamento de antígeno de membrana específico da próstata, seus usos, composição e método de imageamento
WO2025054727A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2025111712A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250108

R150 Certificate of patent or registration of utility model

Ref document number: 7618599

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150